Supporting data for BISMUTH-BASED DRUGS AND AGENTS AS ANTI-SARS-COV-2 AGENTS AND NEPHROTOXICITY SCAVENGERS

<p>Metal compounds have long been used in clinic for the treatment and diagnosis of various diseases (e.g., platinum-based anti-cancer drugs, bismuth-based anti-ulcer drugs and gadolinium-based MRI imaging) and have enormous potential for emerging infectious diseases. For example, COVID-19 pandemic unprecedently triggers global public health issue while effective treatment options remain limited.</p> <p>  </p> <p>Collectively, these findings validate the potential to expedite the development of bismuth (III) based agents and provide novel insights into the molecular basis of metallodrugs and stimulate translational research to flourish.</p>